CollabRx data analytics, focused on informing clinical decision making in molecular medicine, is collaborating with the thoracic oncology program at the University of Chicago Medical Center, a cancer treatment center with clinical and translational research programs in cancer genetics and therapeutics.
The initiative will combine CollabRx content and technology resources with the results of genetic sequencing-based tests conducted at the medical center. The tests are designed to enable physicians to consider a tumor's unique genetic profile in cancer treatment planning.
"This commitment includes consideration of drugs and other therapies that target genetic abnormalities in tumors,” said Ravi Salgia, M.D., Ph.D., vice chair of translational research at the University of Chicago and collaboration leader. “These genetic abnormalities can now be efficiently identified using cancer mutation panels based on next generation sequencing technologies. CollabRx's systems add substantial value to these panels by infusing interpretation and insight from recognized thought leaders who have knowledge of the latest scientific and medical research in molecular oncology and, more importantly, understand how to apply this knowledge to inform treatment planning at the point of care.”
CollabRx will provide a turnkey medical informatics solution by pairing the results of cancer mutational panels conducted by Salgia and colleagues at the medical center with clinically actionable and dynamically updated knowledge provided by CollabRx. Such knowledge includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials. It also is supported by CollabRx's network of over 75 experts and clinical practitioners in the U.S. and Europe.